Universal Health Services’ fair value estimate has inched higher to about $249.94 per share, reflecting slightly stronger long term revenue assumptions and a largely unchanged risk backdrop. The market’s narrative is being reshaped by more constructive Street research following robust Q3 results, even as policy and execution risks keep debate around valuation balanced. Stay tuned to see how investors can monitor these shifting analyst views and track the evolving story around UHS from here.
Stay updated as the Fair Value for Universal Health Services shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Universal Health Services.
🐂 Bullish Takeaways
-
Several firms have turned more constructive after strong Q3 execution, with Mizuho lifting its target to $267 and Raymond James upgrading UHS to Outperform with a $270 target, citing better than expected results and attractive valuation.
-
Barclays and Wells Fargo, both Overweight, raised targets to $263 and $259 respectively, pointing to stronger EBITDA, improved operational execution and solid underlying demand trends as drivers of higher long term earnings power.
-
Analysts reward UHS for clearer guidance and consistent delivery against expectations, with multiple firms extending or rolling their models out to 2027 and applying higher multiples where they see durable core acute growth.
-
Even Morgan Stanley, at Equal Weight with a higher $233 target, highlights “undemanding” valuation and the potential for a re rating if admissions, particularly in behavioral health, continue to improve.
🐻 Bearish Takeaways
-
BofA, despite raising its target to $190, keeps an Underperform rating, arguing that UHS has above average exposure to policy changes and that core results remain weak relative to perceived risks.
-
Wells Fargo explicitly bakes in a higher probability that enhanced exchange subsidies expire, while other firms flag that some of the upside from better execution and cost control may already be reflected in the recent re rating.
-
Across the more cautious research, the message is that further upside in the stock will likely require sustained admissions growth, particularly in behavioral, and continued flawless execution against 2025 2027 EBITDA targets.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
NYSE:UHS Community Fair Values as at Dec 2025
-
Raised full year 2025 consolidated net revenue guidance to a range of $17.306 billion to $17.445 billion, supported by stronger operating trends and a new Medicaid supplemental payment program in Washington, D.C.
-
Expanded its share repurchase authorization by $1.5 billion on October 27, 2025. This brought total approved buyback capacity to $7.6 billion and reinforced management’s focus on shareholder returns.
-
Repurchased 1,314,696 shares, or 2.07% of shares outstanding, for $234.32 million between July 1 and September 30, 2025. This lifted cumulative buybacks under the long running program to 43,123,370 shares, or 53.51%, for $5.84 billion.
-
Removed from the FTSE All World Index. This change may create a technical headwind for index linked flows and could modestly affect trading liquidity and ownership mix.
Story Continues